Zacks Investment Research·4 days ago
New Strong Sell Stocks for July 2ndDRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Alpha Tau Medical Ltd.(DRTS)Earnings, Financials & Key Ratios
DRTS•NASDAQ
$12.64
Price updated Jul 2, 2026
AboutAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA-$41M-17.5%
- Net Income-$43M-34.3%
- EPS (Diluted)-0.53-17.8%
- ROE-61%-41.3%
DRTS Price & Volume
Alpha Tau Medical Ltd. (DRTS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Runway
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Runway
Key Thesis Takeaways
- Alpha Tau Medical remains in a high-risk, pre-revenue clinical stage, characterized by escalating R&D expenditures that reached $9.6M in 2025Q4.
- While the company is building out specialized infrastructure with $26.9M in net PPE, the current cash burn trajectory suggests a precarious financial position.
- Investors should monitor the firm's ability to secure additional funding, as the existing $16.0M cash balance appears insufficient to sustain the current quarterly operating loss of $12.6M.
Verdict Logic
the company's current cash position of $16.0M is insufficient to cover the $32.8M negative free cash flow reported in 2025Q4, indicating a high probability of near-term shareholder dilution.
DRTS Growth Metrics
Alpha Tau Medical Ltd. (DRTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.44%
Return on Capital
10 Years-25.5%
5 Years-25.83%
3 Years-18.74%
Last Year-48.72%
DRTS Recent Earnings
Alpha Tau Medical Ltd. (DRTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.26-100.0%
$0.13
Rev
—
$49,750
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
$63,000
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.14-16.7%
$0.12
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.26vs $0.13-100.0% | —vs $49,750 |
| Q2 2026 | Mar 9, 2026 | $0.14vs $0.13-7.7% | —vs $63,000 |
| Q4 2025 | Nov 20, 2025 | $0.14vs $0.12-16.7% | — |
| Q3 2025 | Aug 11, 2025 | $0.13vs $0.12-8.3% | — |
Based on last 12 quarters of dataView full earnings history →
Latest DRTS News
Recent stock market news and headlines for Alpha Tau Medical Ltd. (DRTS)
GuruFocus·Jun 25, 2026
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
GlobeNewsWire·Jun 23, 2026
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in IsraelAlpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Peers Comparison
Key metrics vs top competitors for Alpha Tau Medical Ltd. (DRTS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.64 | $1.14B | -23.85 | — | — | -61% | — | |
| $15.78 | $1.8B | -12.93 | 8.28% | -25.66% | -50.82% | — | |
| $17.89 | $1.39B | -2.66 | 1.53% | -30.15% | -47.65% | — | |
| $0.26 | $30.87M | -16.74 | 2.68% | -10.76% | -77.48% | — | |
| $1.45 | $15.66M | -1.84 | -100% | -520.35% | -0% | — | |
| $17.76 | $3.36B | -11.03 | 53.44% | -2554.14% | -43.94% | — |
Compare DRTS vs Peers
Alpha Tau Medical Ltd. (DRTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when DRTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRTS Frequently Asked Questions
Alpha Tau Medical Ltd. (DRTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DRTS profitable?
Alpha Tau Medical Ltd. (DRTS) reported a net loss of $42.6M for fiscal year 2025.
Dividend & Returns
What is DRTS's return on equity?
Alpha Tau Medical Ltd. (DRTS) has a return on equity (ROE) of -61.0%. Negative ROE indicates the company is unprofitable.
What is Alpha Tau Medical Ltd.'s free cash flow?
Alpha Tau Medical Ltd. (DRTS) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.